In an extraordinary move, the FDA has withdrawn draft guidance for biosimilars after receiving public comments and 1 citizen petition. But what makes the FDA about-face on biosimilar evaluation so monumental is that it was the direct result of the citizen petition. Filed by one man: Sarfaraz Niazi.
Scientist Invented A New Pathway To Approve Biosimilars – And The FDA Is Listening
